by Fred Dumais | Jun 13, 2023 | News Release
Sixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184% over Q2-22. Sixth consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, a 53% improvement over Q2-22, and down 24% compared to Q1-23 Physicians prescribing Enerzair and...
by Fred Dumais | Jun 7, 2023 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 7 juin 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle divulguera ses résultats financiers et...
by Fred Dumais | Jun 7, 2023 | News Release
MONTREAL, QUEBEC , June 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on...
by Fred Dumais | May 25, 2023 | Communiqué de presse
Les revenus du T2-23 devraient dépasser 13,5 millions $ La perte de BAIIA ajusté du T2-23 devrait être inférieure à 2,0 millions $ Les dépenses d’exploitation du T2-23 resteront conformes à celles des trimestres précédents Les revenus trimestriels...
by Fred Dumais | May 25, 2023 | News Release
Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with prior quarters ENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior year MONTREAL, QUEBEC , May 25, 2023 –...